October 8, 2009

ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

Re: 2009-10 Seasonal Trivalent Influenza Vaccine

In British Columbia, two influenza vaccination programs will be administered this season: the pandemic H1N1 (pH1N1) vaccine and the seasonal trivalent influenza vaccine (TIV). This Admin Circ pertains to seasonal TIV; further details on the pH1N1 vaccine will be provided subsequently. TIV will be offered in two phases this season. Phase 1: persons aged 65 and older, beginning mid-October. Phase 2: all other recommended groups, following the pH1N1 vaccination campaign. Providers will be notified when phase 2 can commence.

The 2009-10 National Advisory Committee on Immunization (NACI) statement on TIV is under preparation. You will be notified when it is available.

Three TIV products will be supplied to BC for this year’s seasonal influenza vaccination campaign. One is manufactured by GSK (Fluviral® S/F) and one by Sanofi-Pasteur (Vaxigrip®). A limited supply of INFLUVAC™ (Solvay Pharma) vaccine will be made available to those who have a history of anaphylactic reaction to thimerosal.

The seasonal influenza vaccines to be marketed in Canada for the 2009-10 season will contain: an A/Brisbane/59/2007(H1N1)-like virus, an A/Brisbane/10/2007(H3N2)-like virus, and a B/Brisbane/60/2008(Victoria lineage)-like virus. Thus, two of the three components of the 2009-10 vaccine (A/H1N1 and A/H3N2) are unchanged from the previous year’s formulation.

In the event that redistribution of influenza vaccine is required, please keep the insulated shipping cartons in which your initial order was shipped. Health Authorities that find they have a surplus of vaccine should promptly notify BCCDC Biologicals Desk by fax (604-707-2581). The Biologicals Desk will advise regarding the management of any surplus vaccine.
Last Season’s (2008-09) Vaccine

Do not use the formulation from 2008-09 for the 2009-10 influenza vaccination campaign. Do not destroy any vaccines locally. All influenza vaccine remaining from the previous year’s program should be returned to the BCCDC as soon as possible upon BCCDC authorization. For instruction on completing the Field Return form, please contact the BCCDC Biologics desk at 604-707-2582.

Please note the following changes to the Communicable Disease Control Manual, Chapter 2 – Immunization Program, Section VII – Biological Products:

Page 31, seasonal trivalent influenza vaccine indications:

- The recommended recipient groups for this season’s public seasonal vaccination program have been categorized according to timelines for administration of seasonal vaccine (i.e., phase 1 and phase 2).
- Those with chronic liver disease, including hepatitis C, have been added to the list of recommended recipients under sub-category 1 (“people at high risk: adults (including pregnant women) and children with the following chronic health conditions”).
- People working with live swine have been removed from the list of recommended recipients under sub-category 1 (“people at high risk”).
  - Pending further evaluation of an association between seasonal TIV and swine influenza risk, swine workers will not be specifically targeted for seasonal influenza vaccination this year. Swine workers who have other risk factors as outlined in the guidelines remain eligible for vaccination.

Page 32, FluViral®:

- A footnote was added to explain that none of the EMEA immunogenicity criteria were met for the 2009-10 H1N1 component of this vaccine in persons over 60 years of age.

Please remove and destroy the following from the Communicable Disease Control Manual, Chapter 2 – Immunization Program, Section VII – Biological Products:

Pages 31 and 33
Pages 32 and 34

Please insert the following replacement pages in the Communicable Disease Control Manual, Chapter 2 – Immunization Program, Section VII – Biological Products:

Pages 31 to 34
If you have any questions or concerns, please contact Dr. Danuta Skowronski, Physician Epidemiologist, Epidemiology Services, BC Centre for Disease Control at Phone: 604-707-2511 or e-mail: danuta.skowronski@bccdc.ca.

Sincerely,

Dr. Monika Naus,
Director, Immunization Programs
Associate Director
Epidemiology Services
BC Centre for Disease Control

pc: Ministry of Healthy Living and Sport:

Dr. Perry Kendall                  Dr. Eric Young
Provincial Health Officer         Deputy Provincial Health Officer

Dr. Bob Fisk                  Craig Thompson
Medical Consultant             Director, CD Prevention -- Immunization
Non-Communicable Disease

Warren O'Briain
Executive Director
Comm Disease and Addiction Prevention